Trial Profile
A Study Assessing the Efficacy and Safety of Bortezomib Based Induction and Maintenance Therapy in Transplant Ineligible Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 25 Jul 2018 New trial record
- 17 Jun 2018 Interim results (n=20) of clinical observation, estimating the efficiency and safety of Bortezomib based induction and maintenance therapy in transplant ineligible patients, presented at the 23rd Congress of the European Haematology Association.